| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 146, Issue 9 2983-2989, Copyright © 1991 by American Association of Immunologists
ARTICLES |
CA Jacobs, PE Baker, ER Roux, KS Picha, B Toivola, S Waugh and MK Kennedy
Department of Immunology, Immunex Research and Development Corporation, Seattle, WA 98101.
To assess the role of IL-1 in the development of experimental autoimmune encephalomyelitis (EAE), the effects of in vivo treatment with IL-1 alpha or an IL-1 antagonist on the clinical course of EAE were evaluated. First, Lewis rats were immunized with guinea pig myelin in CFA and treated for 19 consecutive days with i.p. injections of recombinant human IL-1 alpha. Clinical signs of paralysis in the IL-1 alpha-treated groups were of longer duration and of greater severity compared to placebo injected controls. In addition, more weight loss was observed in the IL-1 alpha-treated groups compared to controls. This enhanced weight loss was not due to IL-1 alpha injections alone as CFA-treated rats injected with IL-1 alpha did not lose weight when compared to placebo injected, CFA-treated controls. Second, soluble mouse rIL-1R (sIL-1R), which binds both IL-1 alpha and IL-1 beta, was given as an IL-1 antagonist. Treatment of guinea pig myelin/CFA immunized rats with sIL-1R for 13 consecutive days significantly delayed the onset of EAE, reduced the severity of paralysis and weight loss, and shortened the duration of disease. Treatment with sIL-1R was most effective in reducing EAE if administered for 15 consecutive days immediately after immunization. Shortened 5-day treatment regimens spanning days 1 to 5, days 6 to 10, or days 11 to 15 after immunization were less effective in reducing EAE. These data suggest that IL-1 may initiate or promote inflammation within the central nervous system. In addition, specifically blocking the biological activity of IL-1 in vivo by soluble receptors may prove beneficial for the treatment of autoimmune or inflammatory diseases.
This article has been cited by other articles:
|
|
 |
|
  T. Kielian, M. Md. Syed, S. Liu, N. K. Phulwani, N. Phillips, G. Wagoner, P. D. Drew, and N. Esen The Synthetic Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Ciglitazone Attenuates Neuroinflammation and Accelerates Encapsulation in Bacterial Brain Abscesses J. Immunol., April 1, 2008; 180(7): 5004 - 5016. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Lisak, J A Benjamins, B Bealmear, B Yao, S Land, L Nedelkoska, and D Skundric Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures Multiple Sclerosis, April 1, 2006; 12(2): 149 - 168. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Matsuki, S. Nakae, K. Sudo, R. Horai, and Y. Iwakura Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis Int. Immunol., February 1, 2006; 18(2): 399 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hooper-van Veen, H. M Schrijver, A. Zwiers, J B. A Crusius, D. L Knol, N. F Kalkers, M. L Laine, F. Barkhof, A S. Pena, C. H Polman, et al. The interleukin-1 gene family in multiple sclerosis susceptibility and disease course Multiple Sclerosis, December 1, 2003; 9(6): 535 - 539. [Abstract] [PDF]
|
|
|
|
|
|
C. Deng, C. Radu, A. Diab, M. F. Tsen, R. Hussain, J. S. Cowdery, M. K. Racke, and J. A. Thomas IL-1 Receptor-Associated Kinase 1 Regulates Susceptibility to Organ-Specific Autoimmunity J. Immunol., March 15, 2003; 170(6): 2833 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Basu, J. K. Krady, M. O'Malley, S. D. Styren, S. T. DeKosky, and S. W. Levison The Type 1 Interleukin-1 Receptor Is Essential for the Efficient Activation of Microglia and the Induction of Multiple Proinflammatory Mediators in Response to Brain Injury J. Neurosci., July 15, 2002; 22(14): 6071 - 6082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Leskovar, L. Moriarty, J. Turek, I. Schoenlein, and R. Borgens The macrophage in acute neural injury: changes in cell numbers over time and levels of cytokine production in mammalian central and peripheral nervous systems J. Exp. Biol., January 6, 2000; 203(12): 1783 - 1795. [Abstract] [PDF]
|
|
|
|
 |
|
 W. A. Banks Characterization of Interleukin-1alpha Binding to Mouse Brain Endothelial Cells J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 665 - 670. [Abstract] [Full Text]
|
|
|
|
|
|
M. G. Netea, B. Jan Kullberg, O. C. Boerman, I. Verschueren, C. A. Dinarello, and J. W. M. Van der Meer Soluble Murine IL-1 Receptor Type I Induces Release of Constitutive IL-1{alpha} J. Immunol., April 15, 1999; 162(8): 4876 - 4881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Rajan, J. D. S. Klein, and C. F. Brosnan The Effect of {gamma}{delta} T Cell Depletion on Cytokine Gene Expression in Experimental Allergic Encephalomyelitis J. Immunol., June 15, 1998; 160(12): 5955 - 5962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Renard, O. Chappey, M.-P. Wautier, M. Nagashima, E. Lundh, J. Morser, L. Zhao, A.-M. Schmidt, J.-M. Scherrmann, and J.-L. Wautier Recombinant Advanced Glycation End Product Receptor Pharmacokinetics in Normal and Diabetic Rats Mol. Pharmacol., July 1, 1997; 52(1): 54 - 62. [Abstract] [Full Text]
|
|
|
|
 |
|
 P.K. Coyle, L.B. Krupp, C. Doscher, Zhidian Deng, and A. Milazzo Clinical and Immunological Effects of Cooling in Multiple Sclerosis Neurorehabil Neural Repair, January 1, 1996; 10(1): 9 - 15. [Abstract] [PDF]
|
|
|
|
 |
|
 C. A. Dinarello and S. M. Wolff The Role of Interleukin-1 in Disease N. Engl. J. Med., January 14, 1993; 328(2): 106 - 113. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
